KLK3 and neoplasm: Moreover, CMV-based vaccines comprising tumor antigens, including melanoma antigens gp100 and TRP2 [19–22], human prostate-specific antigen (PSA) [23], or model antigens like ovalbumin [22, 24], have shown anti-tumor efficacy in prophylactic and therapeutic mouse models.